Research opportunity for people with Down syndrome who have an immune skin condition
One of our newest research initiatives is an NIH-funded clinical trial testing the safety and efficacy of a drug called tofacitinib
Expertise in the co-occurring conditions of Down syndrome helps better understand the complex COVID-19 immune response
Crnic Institute researchers’ discovery could lead to more effective COVID treatment with immune modulatory drugs
Helping lead the NIH data coordinating center for Down syndrome research
Our scientists, data analysts, and administrators have teamed up with Children's Hospital of Philadelphia and Sage Bionetworks for this new initiative
We use state-of-the-art, transformational research platforms to decipher the unique biology and disease spectrum caused by trisomy of chromosome 21.
Our ultimate goal is to enable precision medicine approaches to improve health outcomes in Down syndrome, including the development of new diagnostic and therapeutic tools.
We are the largest geographical cluster of Down syndrome researchers in the world
Comprised of over 50 Principal Investigators and countless more contributing scientists from across the University of Colorado campuses, our researchers bring expertise from a variety of fields.
Together, we are working to decipher the complex mechanisms and multi-faceted health impacts of trisomy 21.
c83a6de7302864d9a5bfff0a001ce385.jpeg?sfvrsn=71209bb_0 "Child with Down syndrome walking")
